Compare VRAX & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | NXTS |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.5M |
| IPO Year | 2021 | 2021 |
| Metric | VRAX | NXTS |
|---|---|---|
| Price | $2.63 | $1.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 481.2K | 18.0K |
| Earning Date | 06-12-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $263,445.00 |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.55 |
| 52 Week High | $13.19 | $23.80 |
| Indicator | VRAX | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 37.14 |
| Support Level | $2.55 | $1.43 |
| Resistance Level | $3.10 | $2.08 |
| Average True Range (ATR) | 0.30 | 0.15 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 4.55 | 6.82 |
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.